Showing results (11-20 of 116) with videos related to

Sort By:
Pageof 12
Journal of Medical Economics|September 12, 2009
Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspectiveLouis Bessette, Nancy Risebrough, Nicole Mittmann, et al.
Arthritis Research & Therapy|September 27, 2023
Effectiveness of a treat-to-target strategy in patients with moderate to severely active rheumatoid arthritis treated with abataceptLouis Bessette, Boulos Haraoui, Emmanouil Rampakakis, et al.
Journal of Clinical Rheumatology : Practical Reports on Rheumatic & Musculoskeletal Diseases|August 30, 2023
Does the Type of Failure and the Choice of the Second Biologic Influence Response and Persistence on Medication in Rheumatoid Arthritis?Louis Bessette, Mohammad Movahedi, George Reed, et al.
The Journal of Rheumatology|April 3, 2012
Treating rheumatoid arthritis to target: a Canadian physician surveyBoulos Haraoui, William Bensen, Louis Bessette, et al.
BMC Musculoskeletal Disorders|July 20, 2016
Hospitalization for musculoskeletal disorders in rheumatoid arthritis patients: a population-based studyMarina Amaral de Ávila Machado, Sasha Bernatsky, Louis Bessette, et al.
Rheumatology International|August 21, 2013
Rheumatoid arthritis pharmacotherapy and predictors of disease-modifying anti-rheumatic drug initiation in the early years of biologic use in Quebec, CanadaJean-Pascal Roussy, Louis Bessette, Elham Rahme, et al.
The Journal of Rheumatology|October 17, 2007
Advantages and limitations of utility assessment methods in rheumatoid arthritisAriel Beresniak, Anthony S Russell, Boulos Haraoui, et al.
The American Journal of Medicine|November 8, 2005
Impact of a general practitioner educational intervention on osteoarthritis treatment in an elderly populationElham Rahme, Denis Choquette, Michele Beaulieu, et al.
Arthritis Research & Therapy|June 8, 2019
Persistence rates of abatacept and TNF inhibitors used as first or second biologic DMARDs in the treatment of rheumatoid arthritis: 9 years of experience from the Rhumadata® clinical database and registryDenis Choquette, Louis Bessette, Evo Alemao, et al.
Arthritis Care & Research|August 2, 2024
Barriers to, Facilitators of, and Interventions to Support Treat-to-Target Implementation in Rheumatoid Arthritis: A Systematic ReviewLaure Gossec, Louis Bessette, Ricardo M Xavier, et al.
Pageof 12